BETANSEBETA DRUGS LIMITED· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 22 Oct, 2026 · 11:13 IST

Beta Drugs H1 FY27: revenue up 29%, profit after tax up about 44%

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDFExplain this filing

BETA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+17.1%Reaction day
₹1679.00
prior close
₹1769.40
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.0%+18.1% vs market
Pharmaceuticals peers, median of 170sector-0.5%+17.6% vs sector

On the reaction day the stock moved 18.1 pts more than Nifty Microcap 250 and 17.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.1
10m
+1.5
15m
+2.7
30m
+6.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+17.1-1.0+18.1-0.5+17.6
Next day
+12.9-3.3+16.2-2.2+15.2
2d
+16.1-2.9+19.1-1.1+17.2
3d
+16.4-1.3+17.7+0.7+15.8
4d
+16.6-1.2+17.8+1.9+14.7
5d
+12.6-0.5+13.1+2.1+10.5
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Beta Drugs reported H1 FY27 consolidated revenue from operations of INR 263.04 crore, up 29.2% from INR 203.6 crore. Earnings before interest, tax, depreciation and amortization rose about 30% to INR 61 crore. Profit after tax attributable to Beta Drugs rose to INR 34.3 crore from INR 23.9 crore. The corresponding margin edged up to 23.18% from 23.08%. Management targets FY27 revenue above INR 535 crore. The review conclusion was unmodified.

Likely market impact

Positive: strong revenue and profit growth, slightly better margins and net cash support sentiment, though results depend on a stronger H2.